Distinguishing Rheumatoid Arthritis from SLE Arthritis
Rheumatoid arthritis and SLE arthritis differ fundamentally in their joint damage patterns, serologic profiles, and inflammatory markers—RA causes erosive, symmetric polyarthritis with elevated CRP and positive anti-CCP antibodies, while SLE arthritis is typically non-erosive with normal CRP despite active disease, positive anti-dsDNA antibodies, and low complement levels.
Clinical Presentation
Joint Involvement Patterns
RA presents with symmetric polyarthritis affecting small joints of the hands and feet, with morning stiffness lasting ≥1 hour, leading to progressive joint destruction and erosions 1. The arthritis is persistently destructive and associated with synovitis detected on examination 1.
SLE arthritis is characterized by inflammation without significant swelling, with tendinitis and tenosynovitis being more prominent features than in RA 2. Approximately 10-35% of SLE patients develop Jaccoud's arthropathy—a non-erosive deforming arthropathy that distinguishes it from RA's erosive disease 3. SLE arthritis is typically non-deforming and non-erosive, though some patients may develop chronic synovitis 2.
Extra-Articular Manifestations
RA patients develop subcutaneous nodules, interstitial lung disease, vasculitis, and inflammatory eye disease as markers of severe disease 1. These manifestations are associated with shortened life expectancy by 3-5 years 1.
SLE presents with multisystem involvement including cutaneous manifestations (77.5%), hematologic abnormalities (72.5%), and renal disease 4. Mucocutaneous involvement includes acute, subacute, and chronic cutaneous lupus lesions 1. Neuropsychiatric manifestations occur frequently, with headache, mood disorders, seizures, and cognitive impairment being most common 1.
Serologic Findings
RA-Specific Markers
Rheumatoid factor and anti-citrullinated protein antibodies (anti-CCP/ACPA) are characteristic of RA 1. High positive RF or ACPA scores 3 points in the 2010 ACR/EULAR classification criteria 1. These antibodies predict erosive disease and help distinguish RA from SLE 3.
SLE-Specific Markers
Anti-double-stranded DNA antibodies correlate with disease activity and active renal disease in SLE, though treatment should not be based solely on antibody titers without clinical activity 1. Anti-Ro, anti-La, and anti-RNP antibodies have prognostic value in SLE 1.
Low complement levels (C3, C4) are associated with active SLE disease, though they lack predictive value for disease flares 1. Anti-phospholipid antibodies associate with thrombotic manifestations and pregnancy complications in SLE 1.
Critical Distinguishing Feature: CRP
CRP is typically elevated in active RA and guides treatment decisions 1. In contrast, SLE patients rarely have elevated CRP levels despite active disease—a significant CRP increase (>50 mg/L) should prompt evaluation for superimposed infection rather than lupus activity 1. This represents a fundamental diagnostic distinction between the two conditions.
Overlap Syndrome: "Rhupus"
When both diseases coexist (rhupus syndrome), patients exhibit symmetrical small joint polyarthritis with features of both conditions 5. These patients have both rheumatoid factor and anti-dsDNA antibodies 5. Rhupus patients show lower renal involvement (10%) compared to pure SLE (25%), but higher rates of interstitial lung disease 6, 4. The initial onset age falls between typical RA and SLE presentations 6.
Treatment Approaches
RA Management
Early aggressive treatment with methotrexate 15-25 mg/week is the cornerstone of RA therapy, with the goal of achieving remission (SDAI ≤3.3 or CDAI ≤2.8) 1. For inadequate response, add sulfasalazine and hydroxychloroquine for triple-DMARD therapy, or escalate to biologic agents including TNF inhibitors, abatacept, tocilizumab, or rituximab 1.
Glucocorticoids should be tapered and discontinued after achieving remission, as long-term use beyond 1-2 years increases risks of cataracts, osteoporosis, and cardiovascular disease 1.
SLE Arthritis Management
Hydroxychloroquine is uniformly recommended for all SLE patients 7. Glucocorticoids should be limited in duration, with early introduction of conventional and/or biologic immunosuppressive therapies to achieve remission or low disease activity 7.
For extrarenal SLE, belimumab and anifrolumab have proven efficacy in high-quality trials 1. Conventional immunosuppressives (methotrexate, azathioprine, mycophenolate) are used despite limited randomized evidence 1.
For lupus nephritis, mycophenolate and cyclophosphamide show equal efficacy, with belimumab and voclosporin approved as add-on therapies 1, 8, 9.
Common Pitfalls
Misdiagnosis is common—many SLE patients are initially diagnosed with RA 3. Key differentiating steps include:
- Check anti-CCP antibodies and CRP levels—positive anti-CCP and elevated CRP favor RA 3
- Obtain imaging to assess for erosions—erosive disease indicates RA, while non-erosive arthropathy suggests SLE 2, 3
- Evaluate for multisystem involvement—renal, hematologic, and cutaneous manifestations point toward SLE 4
- Measure complement levels and anti-dsDNA—low complements with positive anti-dsDNA indicate SLE 1
In patients with features of both diseases, consider rhupus syndrome and test for both RF/anti-CCP and anti-dsDNA/complement levels 6, 4, 5.